Cardiovascular, renal, and metabolic (CVRM) diseases form the fastest-growing global health spectrum, driven by shared risks like obesity, diabetes, and CKD. IQVIA Biotech’s specialized CVRM team combines real-world data, operational expertise, and strong investigator relationships to de-risk studies and accelerate development. With experience across 500+ Phase I–IV trials in five years, the team supports conditions such as heart failure, arrhythmias, CKD, lupus nephritis, obesity, and Type 1/2 diabetes. Their biotech-focused CRO model provides early and late-phase expertise, intelligent analytics, and agile project management to improve recruitment, regulatory alignment, and trial delivery.

Join for free to read